DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Defibrotide
Defibrotide
Characterising the Risk of Major Bleeding in Patients With
Drug Consumption in 2017 - 2020
Pharmacokinetic Profile of Defibrotide in Patients with Renal Impairment
Tracking Form for Applicants for New Technology Add-On Payments Under the Acute Inpatient Prospective Payment System (IPPS) for Federal Fiscal Year (FY) 2017
Defibrotide for the Treatment and Prophylaxis of Hepatic Veno-Occlusive Disease
Antithrombotic Agents in the Management of Sepsis
Antiplatelet Agents for Chronic Kidney Disease
PRAC Draft Agenda of Meeting 11-14 May 2020
Injectable Medication Hcpcs/Dofr Crosswalk
Drug Consumption at Wholesale Prices in 2017 - 2020
Estonian Statistics on Medicines 2013 1/44
Antithrombotic Therapy in COVID-19: Systematic Summary of Ongoing Or Completed Randomized Trials
DEFITELIO (Defibrotide Sodium) Injection, 200 Mg/2.5 Ml
Ghp P&T Minutes September 20, 2016
Head Injury Partial Update
Haematology Veno-Occlusive Disease
Appendix B - Product Name Sorted by Applicant
Protocol for Non-Interventional Studies Based on Existing Data TITLE PAGE Document Number: C30445781-01
Top View
COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/Intellus Worldwide ANATOMICAL CLASSIFICATION
International Nonproprietary Names (Inn) for Biological and Biotechnological Substances
(INN) for Biological and Biotechnological Substances
DEFITELIO® Defibrotide
Estonian Statistics on Medicines 2017 1/42
Formulary Drug Reviews Defibrotide
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice
Page 1 of 22 Plavix (Clopidogrel Bisulfate) Dose, Indications, Adverse
Direct Oral Anticoagulants
DEFITELIO® (Defibrotide) Concentrated Solution for Infusion
Port EU Post
DEFITELIO (Defibrotide Sodium) Injection, for Intravenous Use Monitor Until Signs and Symptoms Resolve
Defibrotide Enhances Fibrinolysis in Human Endotoxemia – A
Product Monograph Including Patient Medication Information
Defitelio, INN Defibrotide
Liste Des Molécules
Defibrotide for the Treatment and Prevention of Hepatic Veno-Occlusive Disease
Hepatic Veno-Occlusive Disease
©Ferrata Storti Foundation
Hepatic Sinusoidal Obstruction Syndrome in the Era of Defibrotide
Platelet Aggregation Inhibitors (PDF)
Auspar Attachment 1: Product Information for Defibrotide
Mini-Review Avoiding Hepatic Veno-Occlusive Disease: What Do We Know and Where Are We Going?
1. NAME of the MEDICINAL PRODUCT Defitelio® 80 Mg/Ml
Cross Discipline Team Leader Review
Outcomes of Paediatric Drug Development from a Labeling
Thrombotic Events and Death in Inpatient-Identified COVID-19 an Analysis in Trinetx Live™
Use of New Oral Anticoagulants in Preventing Ischemic Stroke in Patients with Atrial Fibrillation Travis Hunt Travis
[email protected]
Management of Hepatic Veno-Occlusive Disease (VOD)
Launch of Defitelio (Defibrotide) in the EU Information on an EBMT Registry
Pulmonary Veno-Occlusive Disease in Myeloproliferative Disorder
WHO Drug Information Vol
Defitelio, INN-Defibrotide
LPS DF Version 1.4., 24.07.2017 1 Defibrotide in The
Swiss Public Assessment Report
208114Orig1s000
COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/PBIRG ANATOMICAL CLASSIFICATION
Defitelio, INN Defibrotide
Update in Anticoagulation and Hypercoagulability In
L:\0900\0900PHARMAPPX .Wpd
Jazz Pharmaceuticals Stops Enrollment in Phase 3 Study Evaluating Defibrotide for the Prevention of Veno-Occlusive Disease
Prdefitelio®
Hepatic Veno-Occlusive Disease After Hematopoietic Stem Cell Transplantation: Update on Defibrotide and Other Current Investigational Therapies
(12) Patent Application Publication (10) Pub. No.: US 2013/0095095 A1 Lines (43) Pub
Apixaban Monograph
Purinergic Modulation May Extinguish the COVID-19 Thrombo-Inflammatory Firestorm
Establishment of Framework for Classification/Categorisation and Labelling of Medicinal Drugs and Driving
Successful Treatment with Defibrotide for Sinusoidal Obstruction Syndrome After Hematopoietic Stem Cell Transplantation
2012 Harmonized Tariff Schedule Pharmaceuticals Appendix